ALLERGAN
THE SCIENCE OF REJUVENATION™

Brilliant DISTINCTIONS® PROGRAM

Announcing New Enhancements to the *Brilliant Distinctions*® Consumer Loyalty Program

Scroll down to see Important Safety Information including Boxed Warning for BOTOX® Cosmetic (onabotulinumtoxinA)

Questions? Contact the Call Center at
1-888-324-2745 (9 AM–9 PM EST. M–F)

Physician Enhancements

Earning on JUVÉDERM® XC treatments (or JUVÉDERM®)

Your patients can now earn points when receiving treatments from participating physicians on both BOTOX® Cosmetic and JUVÉDERM® XC treatments!


Issue a Voucher
Step 2: Enter Treatment Information
To issue a voucher, fill in the patient's treatment information below. Vouchers can be issued for BOTOX® Cosmetic or JUVÉDERM® XC treatments (using one syringe or more). If patient has received both treatments, enter both fields.
Patient received a BOTOX® Cosmetic treatment:
BOTOX® Cosmetic Vial Lot #
Required field if issuing voucher for a BOTOX® Cosmetic treatment.
Patient received a JUVÉDERM® XC treatment:
Syringe Amount
1 syringe
Required field if issuing voucher for a JUVÉDERM® XC treatment.
JUVÉDERM® XC Lot #
Enter the first five characters of the lot number (required field for a JUVÉDERM® XC treatment).
Email Address
[email address]
Inform the patient that the confirmation email will be sent to this email address. If incorrect, the patient can update their email address in the "myInfo" section of their Brilliant Distinctions® Program homepage.
Provider Name (optional)
-Select-
Select the appropriate provider name associated with this transaction. Go to Office Preferences to add, edit, or de-activate a provider.
Issue Voucher

Office preferences

You can now maintain a list of office providers to help with reconciliation. Click on the "Office Preferences" link at the top of the homepage to add, edit, or de-activate a provider.



Voucher reminders

After accepting a coupon, a pop-up window will appear to remind you if a BOTOX® Cosmetic or JUVÉDERM® XC treatment was given that day, to issue your patient voucher points.



Reimbursement preferences

You can choose how often you would like to receive reimbursements and reimbursement summary email. You can choose to be reimbursed per transaction (the default setting), weekly, monthly, or quarterly.

Ability to enter provider name

When issuing vouchers and redeeming coupons, you can now add provider names associated with each transaction.


Redeem Coupon(s)
Enter Coupon Code(s) and Transaction Details
To redeem a patient coupon, enter the coupon code(s) and type of treatment or product below. Codes can only apply for one patient at a time.
Coupon Code(s)
Use commas to separate multiple coupons.
Type of In-Office Transaction
(Select all that apply)
Treatment
Product Purchase
BOTOX® Cosmetic (onabotulinumtoxinA)
LATISSE® (bimatoprost ophthalmic solution) 0.03%
JUVÉDERM® XC
VIVITÉ® products
Provider Name (optional)
-Select-
Select the appropriate provider name associated with this transaction. Go to Office Preferences to add, edit, or deactivate a provider.
Continue

Reimbursement confirmation

In addition to the current ways to check your reimbursements (Reconciliation Tab: All Transactions, Bank Statements, Reimbursement Emails), you can now utilize the "Export Coupon History" function on the Reconciliation Tab, which allows you to see what coupons have been redeemed and reimbursed.


RECONCILIATION
REDEEM COUPON(S)
ISSUE VOUCHER
PROGRAM INFO
Click Here to see Important Safety Information including Boxed Warning for BOTOX® Cosmetic (onabotulinumtoxinA) and JUVÉDERM® XC below
Issue a Voucher
To issue a voucher for a patient, either find your patient in the table below or click on the "Issue a Voucher" link to find a patient new to this account number.
Issue a Voucher
Redeem Coupon(s)
To redeem a patient coupon, click on the "Redeem Coupon(s)" link.
Redeem Coupon(s)
Export Coupon History
For details on which coupons have been redeemed and reimbursed click on "Export."
Export

Date Redeemed	Patient Name	Dollar Amount	Code Number	Status	Provider Name	Notes
2/10/2010	Crenshaw, Lawrence	75	N7N7DEVA5			
4/12/2010	Neequaye, Trenaye	25	KFYUFYJF4			
4/12/2010	Crenshaw, Lawrence	25	11NCVQ9MU			

Consumer Enhancements

Patients can now just click "Deposit" to bank points.

Every time your patient receives a BOTOX® Cosmetic or JUVÉVDERM® XC treatment from a participating physician (as long as it has been 3 months since their last BOTOX® Cosmetic treatment), they will automatically receive voucher points that can be deposited into their account with the click of the "Deposit" button on their homepage!

Qualified patients can use the points they earn from BOTOX® Cosmetic or JUVÉDERM® XC to save on LATISSE® (bimatoprost ophthalmic solution) 0.03% at the pharmacy.

Currently, there are some states that only dispense LATISSE® via the pharmacy. Patients will now have the option to create a pharmacy-specific coupon to use in the pharmacy if this applies to where they live.



BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indication

BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses.

CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS
The recommended dosage and frequency of administration for BOTOX® Cosmetic should not be exceeded. Risks resulting from administration at higher dosages are not known.

Lack of Interchangeability Between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive, serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines) have been reported.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of BOTOX® Cosmetic.

PRECAUTIONS
Caution should be used when BOTOX® Cosmetic treatment is used in patients who have an inflammatory skin problem at the injection site, marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin or the inability to substantially lessen glabellar lines by physically spreading them apart.

Information for Patients
Patients should be counseled that if loss of strength, muscle weakness, or impaired vision occur, they should avoid driving a car or engaging in other potentially hazardous activities.

Pregnancy
Administration of BOTOX® Cosmetic is not recommended during pregnancy. There are no adequate and well-controlled studies of BOTOX® Cosmetic in pregnant women.

Nursing Mothers
It is not known whether BOTOX® Cosmetic is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BOTOX® Cosmetic is administered to a nursing woman.

ADVERSE REACTIONS

General
The most serious adverse events reported after treatment with botulinum toxin include spontaneous reports of death, sometimes associated with anaphylaxis, dysphagia, pneumonia, and/or other significant debility.

There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease.

The most frequently reported adverse events following injection of BOTOX® Cosmetic include blepharoptosis and nausea.

Overdosage

Excessive doses of BOTOX® Cosmetic may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis.

In the event of suspected or actual overdosage, please contact your local or state health department to process a request for antitoxin through the Center of Disease Control and Prevention (CDC). If you do not receive a response within 30 minutes, please contact the CDC directly at 1-770-488-7100.

Please see BOTOX® Cosmetic full Prescribing Information, including Medication Guide.